Table 2.

Genotypic distribution for IL-28B gene polymorphism when patient group (groups “1+2+3”) was compared to control group.

SNPs	Genotype/allele distribution	Healthy controls n = 600	HCV patients n = 678	OR (95% C.I.)	χ 2	P value
rs8105790				2.784 (2.340–3.311)	137.99	<0.0001
	CC	16 (2.7%)	159 (23.4%)
	CT	233 (38.8%)	280 (41.3%)
	TT	351 (58.5%)	239 (35.3%)
	C	265 (22.1%)	598 (44.1%)
	T	935 (77.9%)	758 (55.9%)
	CC + CT versus TT			2.589 (2.065–3.247)	69.23	<0.0001
	CC versus CT + TT			0.089 (0.053–0.152)	116.35	<0.0001
rs8099917				2.552 (2.062–3.160)	77.16	<0.0001
	GG	14 (2.3%)	104 (15.3%)
	GT	114 (19.0%)	138 (20.4%)
	TT	472 (78.7%)	436 (64.3%)
	G	142 (11.8%)	346 (25.5%)
	T	1058 (88.2%)	1010 (74.5%)
	GG + GT versus TT			2.047 (1.593–2.630)	31.91	<0.0001
	GG versus GT + TT			0.132 (0.075–0.233)	64.25	<0.0001
rs7248668				1.863 (1.533–2.264)	39.72	<0.0001
	AA	58 (9.7%)	94 (13.9%)
	AG	79 (13.2%)	172 (25.4%)
	GG	463 (77.2%)	412 (60.7%)
	A	195 (16.3%)	360 (26.5%)
	G	1005 (83.8%)	996 (73.5%)
	AA + AG versus GG			2.182 (1.708–2.788)	39.65	<0.0001
	AA versus AG + GG			0.665 (0.470–0.941)	5.35	0.0206
rs12979860				1.476 (1.250–1.743)	21.15	<0.0001
	TT	59 (9.9%)	73 (10.8%)
	CT	230 (38.6%)	367 (54.1%)
	CC	307 (51.5%)	238 (35.1%)
	T	348 (29.2%)	513 (37.8%)
	C	844 (70.8%)	843 (62.2%)
	TT + CT versus CC			1.964 (1.568–2.460)	34.88	<0.0001
	TT versus CT + CC			0.911 (0.634–1.308)	0.26	0.61213
rs12980275				1.765 (1.488–2.093)	42.97	<0.0001
	GG	59 (9.8%)	89 (13.12%)
	AG	184 (30.7%)	327 (48.2%)
	AA	357 (59.5%)	262 (38.6%)
	G	302 (25.2%)	505 (37.2%)
	A	898 (74.8%)	851 (62.8%)
	GG + AG versus AA			2.333 (1.863–2.920)	55.44	<0.0001
	GG versus AG + AA			0.722 (0.509–1.023)	3.37	0.06631

Risk allele marked in BOLD letter.